Condition

Metastatic Malignant Neoplasm in the Bone

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 24 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials24
Recruiting3
Common interventions25
Lead sponsors shown13
Advertisement

Clinical trials

24 shown
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate CancerNCT04489719 · 2021-04-16
RECRUITING
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialNCT04693377 · 2021-03-16
RECRUITING
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial CancerNCT01050504 · 2009-08-01
RECRUITING
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to BonesNCT06982222 · 2026-10-01
WITHDRAWN
Efficacy of Ra-223 in PSMA PET Optimally Selected PatientsNCT05924672 · 2024-08-30
ACTIVE_NOT_RECRUITING
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to BonesNCT04616547 · 2021-12-18
TERMINATED
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate CancerNCT04754425 · 2021-07-15
TERMINATED
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation TherapyNCT04928820 · 2021-06-16
TERMINATED
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyNCT04071236 · 2020-10-14
ACTIVE_NOT_RECRUITING
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the BonesNCT04090398 · 2020-08-04
ACTIVE_NOT_RECRUITING
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate CancerNCT03649841 · 2020-06-29
TERMINATED
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate CancerNCT03796767 · 2019-09-09
COMPLETED
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisNCT03691493 · 2019-02-08
COMPLETED
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland CancersNCT03749460 · 2019-01-15
COMPLETED
Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast CancerNCT03012230 · 2017-12-06
COMPLETED
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate CancerNCT03204812 · 2017-07-14
COMPLETED
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerNCT02565901 · 2016-02-29
TERMINATED
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate CancerNCT02499835 · 2015-07-01
COMPLETED
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate CancerNCT02429804 · 2015-04-01
TERMINATED
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves SurvivalNCT02364557 · 2014-12-24
COMPLETED
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing SarcomaNCT02306161 · 2014-12-12
ACTIVE_NOT_RECRUITING
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide TherapyNCT02099864 · 2014-02-05
COMPLETED
Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-TNCT01833208 · 2013-07-03
COMPLETED
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone MetastasesNCT00936975 · 2009-09-01
COMPLETED

Common interventions

Trial status mix

COMPLETED10
TERMINATED6
ACTIVE_NOT_RECRUITING4
RECRUITING3
WITHDRAWN1

Phase mix

PHASE216
PHASE17
NA2
PHASE32
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.